Q3 Earnings Forecast for MetaVia Issued By Zacks Research

MetaVia Inc. (NASDAQ:MTVA) – Zacks Research issued their Q3 2026 EPS estimates for MetaVia in a research note issued on Tuesday, March 31st. Zacks Research analyst D. Bautz forecasts that the company will post earnings per share of ($0.94) for the quarter. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share.

MTVA has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Finally, HC Wainwright lowered their price target on shares of MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $26.50.

MetaVia Stock Performance

Shares of MTVA opened at $1.25 on Wednesday. The stock has a market capitalization of $2.75 million, a PE ratio of -0.15 and a beta of 0.35. The company’s fifty day moving average is $1.70 and its 200 day moving average is $6.66. MetaVia has a fifty-two week low of $1.17 and a fifty-two week high of $23.10.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia as of its most recent SEC filing. Institutional investors and hedge funds own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.